Stay updated with breaking news from Allied Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist...
BOSTON & LONDON, Feb. 09, 2024 -- Centessa Pharmaceuticals plc announced that data from an additional 52-weeks of continuous treatment from the third year of the ongoing Phase 2a study of...
Sobi® will present new data at the 17th European Association of Haemophilia and Allied Disorders conference in Frankfurt from 6-9 February 2024. The studies that will be presented support Sobi's...
Three million Canadians suffer from rare illnesses. Although drugs exist for some of them, they are often prohibitively expensive. Read on.
Will universal government-run pharmacare benefit Canadians with rare disorders? We fear not. Find out more.